Bend Bioscience Expands Commercial Spray Drying and Granulation Capabilities
Innovation, science, and pharmaceutical services partner, Bend Bioscience, is expanding its Gainesville, Georgia facility with the addition of a commercial-scale spray dryer and a Gerteis drug granulation system. With the increased capabilities, the company will be able to provide technologically advanced absorption- and bioavailability-enhanced products in addition to comprehensive clinical and commercial scale oral dose forms.
The new spray drying suite will include a GEA PSD-4, adjacent secondary vacuum drying systems, multiple tank sizes for flexibility, and a dual-stage condenser. Additionally, the expanded facility will provide customers with the ability to process highly potent APIs. The new equipment is being shipped to the Georgia facility in April and the company expects to commence installation immediately.
Bend Bioscience, a leading innovation, science, and pharmaceutical services partner, today announced the addition of a commercial-scale spray dryer and a Gerteis dry granulation system at its 120,000-square-foot facility in Gainesville, Georgia. The addition of this equipment will expand the Gainesville facility’s capabilities to provide technologically advanced absorption- and bioavailability-enhanced products, and comprehensive clinical and commercial scale oral dose forms.
Featuring a state-of-the-art GEA PSD-4, the new spray drying suite will include adjacent secondary vacuum drying systems, multiple tank sizes to accommodate flexible campaigns and batch sizes, a dual-stage condenser capable of handling a wide range of process solvents, and the ability to process highly potent APIs. The new equipment is being shipped to the Gainesville facility this month and the installation process will begin immediately to align with potential customer timelines.
“Our FDA-inspected Gainesville site is known for its exceptional customer service, and these latest additions demonstrate our commitment to providing strong, innovative, and comprehensive solutions that empower our customers to bring their transformative therapies to market,” said Owen Murray, CEO of Bend Bioscience. “This expansion not only reinforces our position as a leader in the pharmaceutical services industry, but also allows us to meet the demands of significant near-term growth through our network of capabilities and expertise in enhancing pharmacokinetics, particle engineering and modified release forms.”
These new capabilities complement the company’s clinical development expertise in spray dried dispersions at its site in Bend, Oregon, and strengthen Bend Bioscience’s ability to support both existing and new early-phase customers seeking bioavailability solutions and oral dose forms from early-phase development to reliable commercial supply of marketed products.
The Gainesville facility specializes in oral solid dosage forms, and is a center of excellence for commercial manufacturing, modified release and multiparticulates. It is equipped to handle DEA schedule (I-V) and potent compounds, and has its own analytical, late-phase tech transfer teams, and provides specialist packaging capabilities.
For more, please find the original story source here.